
Analysis of Drug Impurities
Wiley (Publisher)
Published on 12. November 2007
Software
Other digital
288 pages
978-0-470-98874-9 (ISBN)
Description
A key component of the overall quality of a pharmaceutical is control of impurities, as their presence, even in small amounts, may affect drug safety and efficacy. The identification and quantification of impurities to acceptable standards presents a significant challenge to the analytical chemist. Analytical science is developing rapidly and provides increasing opportunity to identify the structure, and therefore the origin and safety implications of these impurities, and the challenges of their measurement drives the development of modern quantitative methods. Written for both practicing and student analytical chemists, Analysis of Drug Impurities provides a detailed overview of the challenges and the techniques available to permit accurate identification and quantification of drug impurities.
Reviews / Votes
"This book can be recommended to not only analytical chemists but also scientists working in the field of pharmaceutical analysis." (Analytical and Bioanalytical Chemistry, November 2007)More details
Language
English
Place of publication
Hoboken
United Kingdom
Publishing group
John Wiley and Sons Ltd
Target group
Professional and scholarly
Dimensions
Height: 241 mm
Width: 167 mm
Thickness: 21 mm
Weight
660 gr
ISBN-13
978-0-470-98874-9 (9780470988749)
Copyright in bibliographic data and cover images is held by Nielsen Book Services Limited or by the publishers or by their respective licensors: all rights reserved.
Schweitzer Classification
Other editions
Additional editions

Richard J. Smith | Michael L. Webb
Analysis of Drug Impurities
E-Book
05/2008
Wiley-Blackwell
€179.99
Available for download
Persons
Richard Smith is Director, Analytical Sciences at GlaxoSmithKline Research and Development, Tonbridge, UK and Michael Webb is Director, Analytical Sciences at GlaxoSmithKline Research and Development, Stevenage, UK. Contributors to the book: Dr Linda Ng Dr George Lunn Dr Patrick Faustino Dr Dave Elder Dr Mark R. Hadley Dr Peter Skett Dr Gary E. Martin Dr Ian Jones Dr Janet Hammond Dr Gerald Terfloth Dr Frank Cottee
Editor
GlaxoSmithKline, Stevenage, Herfordshire, UK
GlaxoSmithKline, Stevenage, Herfordshire, UK
Content
1. Organic impurities in drug substances: origin, control and measurement. . 2. Organic impurities in drug products: origin, control and measurement. 3. Stereochemical impurities. . 4. Low level measurement of potent toxins. . 5. A systematic approach to impurity identification. . 6. The use chromatography and on-line structural elucidation using spectroscopy . 7. Preparative isolation of impurities. . 8. Impact of continuous processing. References. Index